Key Takeaway: Jasper Therapeutics has successfully closed its acquisition of Kira Pharmaceuticals, enhancing its portfolio with clinical stage assets targeting immunologically-driven disorders. The company also completed a PIPE financing, securing $132 million in gross proceeds. This strategic move positions Jasper Therapeutics for future growth and development in the biopharma sector.
Market Sentiment Analysis
POSITIVE FACTORS
Successful acquisition of Kira Pharmaceuticals.
Creation of a robust portfolio of clinical stage assets.
Significant PIPE financing raising $132 million.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
7%
average across 4 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Isradipine
Phase 1 · Nicotine Dependence
Full Press Release Details
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug.
Frequently Asked Questions
What was the recent acquisition by Jasper Therapeutics?
Jasper Therapeutics recently acquired Kira Pharmaceuticals.
How much did Jasper Therapeutics raise in PIPE financing?
Jasper Therapeutics raised $132 million in gross proceeds from PIPE financing.
What is the focus of Jasper's clinical stage assets?
The clinical stage assets focus on immunologically-driven disorders.